{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:16:55Z","timestamp":1780633015653,"version":"3.54.1"},"reference-count":164,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3654,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1093\/annonc\/mdp492","type":"journal-article","created":{"date-parts":[[2009,11,10]],"date-time":"2009-11-10T02:09:55Z","timestamp":1257818995000},"page":"1913-1927","source":"Crossref","is-referenced-by-count":544,"title":["Triple-negative breast cancer\u2014current status and future directions"],"prefix":"10.1016","volume":"20","author":[{"given":"O.","family":"Gluz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Nitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdp492_bb0010","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/djm059","article-title":"Breast cancer incidence, 1980\u20132006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status","volume":"99","author":"Glass","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp492_bb0015","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdp492_bb0020","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0025","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp492_bb0030","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp492_bb0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp492_bb0040","article-title":"Genotypic characterization of phenotypically defined triple-negative breast cancer","volume":"27","author":"Sparano","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0045","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdp492_bb0050","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdp492_bb0055","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jnci\/80.9.691","article-title":"Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue","volume":"80","author":"Dairkee","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp492_bb0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature04372","article-title":"Generation of a functional mammary gland from a single stem cell","volume":"439","author":"Shackleton","year":"2006","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdp492_bb0070","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdp492_bb0075","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/0008-5472.CAN-07-2017","article-title":"Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype","volume":"68","author":"Sarrio","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0080","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/bcr2108","article-title":"The CD44+\/CD24- phenotype is enriched in basal-like breast tumors","volume":"10","author":"Honeth","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0085","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0095","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1471-2407-7-134","article-title":"Use of immunohistochemical markers can refine prognosis in triple negative breast cancer","volume":"7","author":"Tischkowitz","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-007-9756-8","article-title":"Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients","volume":"111","author":"Tan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0105","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1158\/1078-0432.CCR-08-2132","article-title":"Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes","volume":"15","author":"Rakha","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0110","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers?","volume":"123","author":"Bertucci","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0115","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1158\/1078-0432.CCR-06-1842","article-title":"Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy","volume":"13","author":"Diallo-Danebrock","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0120","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/01.LAB.0000038508.86221.B3","article-title":"Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis","volume":"82","author":"Korsching","year":"2002","journal-title":"Lab Invest"},{"key":"10.1093\/annonc\/mdp492_bb0125","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0130","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-07-1658","article-title":"Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype","volume":"14","author":"Cheang","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0135","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS-25","article-title":"GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer","volume":"69","author":"Sparano","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-008-0295-8","article-title":"Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers","volume":"118","author":"Nofech-Mozes","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2559.2006.02453.x","article-title":"Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast","volume":"49","author":"Fulford","year":"2006","journal-title":"Histopathology"},{"key":"10.1093\/annonc\/mdp492_bb0150","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1158\/1078-0432.CCR-04-2424","article-title":"Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype","volume":"11","author":"Lakhani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/modpathol.3800528","article-title":"Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma","volume":"19","author":"Livasy","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdp492_bb0160","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0046-8177(99)90028-X","article-title":"Myoepithelial differentiation in high-grade invasive ductal carcinomas with large central acellular zones","volume":"30","author":"Tsuda","year":"1999","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdp492_bb0165","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00000478-200002000-00005","article-title":"Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases","volume":"24","author":"Tsuda","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdp492_bb0170","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.543","article-title":"Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)","volume":"27","author":"Lin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0175","first-page":"10","volume":"49","author":"Reis-Filho","year":"2006","journal-title":"Metaplastic breast carcinomas are basal-like tumours. Histopathology"},{"key":"10.1093\/annonc\/mdp492_bb0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/path.1845","article-title":"Typical medullary breast carcinomas have a basal\/myoepithelial phenotype","volume":"207","author":"Jacquemier","year":"2005","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdp492_bb0185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-008-0197-9","article-title":"Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis","volume":"117","author":"Weigelt","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0190","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-08-1005","article-title":"Risk factors for triple-negative breast cancer in women under the age of 45 years","volume":"18","author":"Dolle","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdp492_bb0195","doi-asserted-by":"crossref","first-page":"10608","DOI":"10.1158\/0008-5472.CAN-07-2142","article-title":"Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-007-9632-6","article-title":"Epidemiology of basal-like breast cancer","volume":"109","author":"Millikan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0205","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1055-9965.EPI-06-0806","article-title":"Differences in risk factors for breast cancer molecular subtypes in a population-based study","volume":"16","author":"Yang","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdp492_bb0210","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.1200\/JCO.2006.06.5664","article-title":"Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer","volume":"24","author":"Haffty","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0215","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0220","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/cncr.22618","article-title":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype","volume":"109","author":"Bauer","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0225","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdp492_bb0230","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr1622","article-title":"Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342","volume":"8","author":"Harris","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0235","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.22836","article-title":"Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients","volume":"110","author":"Morris","year":"2007","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0240","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0245","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cncr.23243","article-title":"The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999\u20132004","volume":"112","author":"Brown","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0250","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/bcr2261","article-title":"Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors","volume":"11","author":"Kwan","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0255","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10552-009-9331-1","article-title":"The epidemiology of triple-negative breast cancer, including race","volume":"20","author":"Trivers","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1093\/annonc\/mdp492_bb0260","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.1038","article-title":"The association of metabolic syndrome with triple-negative breast cancer","volume":"27","author":"Maiti","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0265","article-title":"Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: a hypothesis generating study","volume":"24","author":"Nitz","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0270","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/bcr2242","article-title":"Triple-negative breast cancers are increased in black women regardless of age or body mass index","volume":"11","author":"Stead","year":"2009","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0275","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10549-007-9810-6","article-title":"Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women","volume":"111","author":"Yang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0280","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1158\/1055-9965.EPI-04-0394","article-title":"A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors","volume":"14","author":"Collett","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdp492_bb0285","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1148\/radiol.2503081054","article-title":"Triple-negative breast cancer: correlation between MR imaging and pathologic findings","volume":"250","author":"Uematsu","year":"2009","journal-title":"Radiology"},{"key":"10.1093\/annonc\/mdp492_bb0290","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1200\/JCO.2007.14.6134","article-title":"Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0295","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/annonc\/mdn683","article-title":"Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment","volume":"20","author":"Moon","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0300","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23226","article-title":"Comparison of triple-negative and estrogen receptor-positive\/progesterone receptor-positive\/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose\/positron emission tomography imaging parameters","volume":"112","author":"Basu","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0305","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdp492_bb0310","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ijc.21004","article-title":"High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses","volume":"116","author":"Abd El-Rehim","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0315","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0320","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2008.18.1024","article-title":"Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial","volume":"27","author":"Hugh","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0325","article-title":"Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial","volume":"26","author":"Burnell","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0330","article-title":"Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA)","volume":"24","author":"Jacquemier","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0335","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jcp.2005.033043","article-title":"Basal-like breast carcinomas: clinical outcome and response to chemotherapy","volume":"59","author":"Banerjee","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdp492_bb0340","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1078-0432.CCR-05-2281","article-title":"Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas","volume":"12","author":"Rodriguez-Pinilla","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0345","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","article-title":"Pattern of metastatic spread in triple-negative breast cancer","volume":"115","author":"Dent","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0350","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1002\/cncr.24573","article-title":"Time to disease recurrence in basal-type breast cancers","volume":"115","author":"Dent","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0355","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/cncr.24094","article-title":"Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation","volume":"115","author":"Freedman","year":"2009","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0360","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","article-title":"Estrogen receptor, progesterone receptor, her-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group","volume":"26","author":"Kyndi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0365","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","article-title":"Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy","volume":"26","author":"Nguyen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0370","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1524-4741.2008.00622.x","article-title":"Impact of triple negative phenotype on breast cancer prognosis","volume":"14","author":"Kaplan","year":"2008","journal-title":"Breast J"},{"key":"10.1093\/annonc\/mdp492_bb0375","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.21.7075","article-title":"Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel","volume":"27","author":"Millar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0380","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/cncr.23930","article-title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer","volume":"113","author":"Lin","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0385","article-title":"Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors","volume":"26","author":"Heitz","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0390","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdn682","article-title":"Survival among women with triple receptor-negative breast cancer and brain metastases","volume":"20","author":"Dawood","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0395","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-008-9769-0","article-title":"Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis","volume":"93","author":"Saip","year":"2008","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdp492_bb0400","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/cncr.23468","article-title":"Survival in patients with brain metastases from breast cancer","volume":"112","author":"Eichler","year":"2008","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0405","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.1027","article-title":"The role of systemic treatment after whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases: differences depending on biological subtype","volume":"27","author":"Niwinska","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0410","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.1028","article-title":"A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients","volume":"27","author":"Pusztai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0415","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","article-title":"The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2","volume":"20","author":"Lakhani","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0420","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/0008-5472.CAN-03-2970","article-title":"The prognostic implication of the basal-like (cyclin E high\/p27 low\/p53+\/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer","volume":"64","author":"Foulkes","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0425","article-title":"Prevalence of BRCA1 mutations in triple negative breast cancer (BC)","volume":"24","author":"Kandel","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0430","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","article-title":"The prevalence of BRCA mutations among young women with triple-negative breast cancer","volume":"9","author":"Young","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0435","first-page":"1222","article-title":"Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations","volume":"57","author":"Tirkkonen","year":"1997","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0440","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/0008-5472.CAN-03-2570","article-title":"Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers","volume":"64","author":"Wang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0445","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.20366","article-title":"Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer","volume":"45","author":"Bergamaschi","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0450","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.onc.1202106","article-title":"p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours","volume":"17","author":"Crook","year":"1998","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdp492_bb0455","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1038\/sj.onc.1210885","article-title":"The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1\/BRCA2-deficient and ER\/PR\/ERBB2-triple-negative breast cancer","volume":"27","author":"Tommiska","year":"2008","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdp492_bb0460","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1158\/0008-5472.CAN-07-2536","article-title":"Integrated profiling of basal and luminal breast cancers","volume":"67","author":"Adelaide","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0465","author":"Winer","year":"2009","journal-title":"Progress in the treatment BRCA1 or 2 deficient and triple negative breast cancer"},{"key":"10.1093\/annonc\/mdp492_bb0470","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"26","author":"Turner","year":"2007","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdp492_bb0475","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0b013e31819c1c93","article-title":"Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers","author":"Collins","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1093\/annonc\/mdp492_bb0480","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/0008-5472.CAN-04-0107","article-title":"Cell-type-specific responses to chemotherapeutics in breast cancer","volume":"64","author":"Troester","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0485","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djj052","article-title":"Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis","volume":"98","author":"Sotiriou","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp492_bb0490","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2006.07.1522","article-title":"Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade","volume":"25","author":"Loi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0495","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.2008.18.5934","article-title":"Genomic grade index is associated with response to chemotherapy in patients with breast cancer","volume":"27","author":"Liedtke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0500","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.559","article-title":"Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"27","author":"Ono","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0505","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.lba515","article-title":"Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: the I-SPY TRIAL (CALGB 150007\/150012, ACRIN 6657)","volume":"27","author":"Esserman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0510","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0515","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp492_bb0520","article-title":"Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease","volume":"106","author":"Slamon","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0525","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS-705","article-title":"A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy","volume":"69","author":"Di Leo","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0530","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/annonc\/mdn039","article-title":"p53 status and efficacy of primary anthracyclines\/alkylating agent-based regimen according to breast cancer molecular classes","volume":"19","author":"Bidard","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0535","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.546","article-title":"Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: a tissue microarray","volume":"27","author":"Berrada","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0540","article-title":"47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients","volume":"106","author":"Le Tourneau","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0545","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/annonc\/mdm551","article-title":"Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial","volume":"19","author":"Gluz","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0550","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/jco.2009.27.15_suppl.519","article-title":"Anthracyclines in basal breast cancer: the NCIC-CTG trial MA5 comparing adjuvant CMF to CEF","volume":"27","author":"Cheang","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0555","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMoa071167","article-title":"HER2 and response to paclitaxel in node-positive breast cancer","volume":"357","author":"Hayes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp492_bb0560","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0565","article-title":"Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): final results and analysis of markers predicting response to treatment","volume":"27","author":"Huober","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0570","article-title":"Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): relevance of HER2 and hormonal status (HR)","volume":"25","author":"Rodriguez-Lescure","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0575","article-title":"A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer","volume":"25","author":"Loesch","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0580","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp492_bb0585","first-page":"6069","article-title":"Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER\/PR\/HER2-negative breast cancer resistant to anthracyclines and taxanes","volume":"106","author":"Rugo","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2009.07.015","article-title":"Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer","author":"Pivot","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0595","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/jnci\/djh312","article-title":"The role of BRCA1 in the cellular response to chemotherapy","volume":"96","author":"Kennedy","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdp492_bb0600","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cc.5.9.2726","article-title":"BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance","volume":"5","author":"Chabalier","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1093\/annonc\/mdp492_bb0605","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1158\/0008-5472.CAN-03-4080","article-title":"BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3","volume":"64","author":"Gilmore","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0610","doi-asserted-by":"crossref","first-page":"12117","DOI":"10.1073\/pnas.0702955104","article-title":"Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer","volume":"104","author":"Rottenberg","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdp492_bb0615","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jmg.39.8.608","article-title":"A significant response to neoadjuvant chemotherapy in BRCA1\/2 related breast cancer","volume":"39","author":"Chappuis","year":"2002","journal-title":"J Med Genet"},{"key":"10.1093\/annonc\/mdp492_bb0620","article-title":"BRCA1 gene expression signature predicts for anthracycline-chemosensitivity in triple-negative breast cancer","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0625","article-title":"Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple-negative breast cancers?","volume":"25","author":"Petit","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0630","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1200\/JCO.2008.19.9067","article-title":"Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Kriege","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0635","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI30866","article-title":"The p63\/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers","volume":"117","author":"Leong","year":"2007","journal-title":"J Clin Invest"},{"issue":"Suppl","key":"10.1093\/annonc\/mdp492_bb0640","article-title":"Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients","volume":"27","author":"Gronwald","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0645","article-title":"Neoadjuvant cisplatin in triple-negative breast cancer","volume":"100","author":"Garber","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0650","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00280-007-0652-z","article-title":"Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel","volume":"62","author":"Torrisi","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdp492_bb0655","article-title":"Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): safety and efficacy","volume":"27","author":"Ryan","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0660","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/annonc\/mdn748","article-title":"Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer","volume":"20","author":"Frasci","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0665","first-page":"5063","article-title":"Preliminary recurrence and survival analysis of patients (pts) receiving neoadjuvant q4week carboplatin and weekly paclitaxel \u00b1 weekly trastuzumab in resectable and locally advanced breast cancer: update of BrUOG BR-95","volume":"106","author":"Sikov","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0670","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.625","article-title":"Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): retrospective analysis of 125 patients","volume":"27","author":"Leone","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0675","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/annonc\/mdn395","article-title":"Platinum-based chemotherapy in triple-negative breast cancer","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0680","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/ijc.24090","article-title":"Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy","volume":"124","author":"Uhm","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0685","first-page":"308","article-title":"Preliminary results of a randomized phase II study of weekly irinotecan\/carboplatin with or without cetuximab in patients with metastatic breast cancer","volume":"106","author":"O'Shaughnessy","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0690","article-title":"Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine\/carboplatin (G\/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial","volume":"27","author":"O'Shaughnessy","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdp492_bb0695","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdp492_bb0700","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer","volume":"8","author":"Cleator","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0705","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdm522","article-title":"MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer","volume":"19","author":"Eralp","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0710","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10549-007-9796-0","article-title":"\u03b1B-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer","volume":"111","author":"Ivanov","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0715","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Hoeflich","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0720","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-006-9250-8","article-title":"Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007","volume":"100","author":"Altundag","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0725","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0014-5793(92)81458-X","article-title":"The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles","volume":"314","author":"Glenney","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1093\/annonc\/mdp492_bb0730","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10549-006-9184-1","article-title":"Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer","volume":"99","author":"Pinilla","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0735","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdp492_bb0740","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS-1038","article-title":"Pre-clinical activity of the PARP inhibitor AZD2281 in human breast cancer cell lines and in combination with DNA damaging agents","volume":"69","author":"Finn","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0745","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdp492_bb0750","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.cra501","article-title":"Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer","volume":"27","author":"Tutt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0755","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdp492_bb0760","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.1009","article-title":"TBCRC 001: eGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer","volume":"26","author":"Carey","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0765","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdp492_bb0770","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0775","article-title":"Basal-like breast tumor-derived cell lines are growth inhibited and radiosensitized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors","volume":"88","author":"Sartor","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0780","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection","volume":"67","author":"Huang","year":"2007","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0785","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-006-9463-x","article-title":"Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type\/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro","volume":"105","author":"Finn","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdp492_bb0790","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS-3118","article-title":"Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059","volume":"69","author":"Finn","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0795","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1093\/annonc\/mdp492_bb0800","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS-1077","article-title":"Significantly higher expression of vascular endothelial growth factor (VEGF) and shorter survival after recurrences in premenopausal node negative patients with triple negative breast cancer","volume":"69","author":"Linderholm","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0805","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.SABCS-1087","article-title":"Vascular endothelial growth factor receptor 2 is a significant negative prognostic biomarker in triple-negative breast cancer: results from a controlled randomised trial of premenopausal breast cancer","volume":"69","author":"Ryden","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdp492_bb0810","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.569","article-title":"Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer","volume":"27","author":"Andre","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0815","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdp492_bb0820","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(07)61232-X","article-title":"MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study","volume":"370","author":"Kuhl","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdp492_bb0825","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2008.17.2650","article-title":"Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose","volume":"27","author":"Schwarz-Dose","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419398813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419398813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/20\/12\/1913\/557207\/mdp492.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T13:24:37Z","timestamp":1685193877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419398813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":164,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0923753419398813"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdp492","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}